NCT03044977View on ClinicalTrials.gov

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 7, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Neuroendocrine Tumor, MalignantNeuroendocrine Tumor Gastrointestinal, Hormone-Secreting
Interventions
DRUG

90Y-DOTA-3-Tyr-Octreotide

Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide. For intravenous administration only.

DRUG

131I-MIBG

Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide. For intravenous administration only.

Trial Locations (1)

52242

Holden Comprehensive Cancer Center, Iowa City

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Holden Comprehensive Cancer Center

OTHER

lead

David Bushnell

OTHER